$33M in Series B investment was received by Brixton Biosciences, a clinical stage life sciences firm located in Cambridge, Massachusetts that is creating innovative treatments for both acute and chronic pain.
Investors
- Schooner Capital
- Catalyst Health Ventures
- Excelestar Ventures
- Sparta Group
- PV Capital Management
- SV Health Investors
Use of funds
The money will be used by the business to start crucial clinical trials in indications related to both acute and chronic pain.
With the help of the funding, the business will be able to conduct two important clinical trials to treat osteoarthritis-related knee pain and to treat knee replacement surgery. In the end, the Neural Ice platform will be able to treat a variety of pain indications using an easy-to-use, extremely long-acting injectable drug-free nerve block. In order to carry on this strategy, Brixton has added Reggie Groves, a seasoned professional with a proven track record at Medtronic, to its Board of Directors and named Dr. Michael Fishman, a Key Opinion Leader in Pain Management, as Chief Medical Officer.
About Brixton Bioscience
Brixton Biosciences, a clinical stage life sciences firm founded as a spin-out from Massachusetts General Brigham, is headed by CEO Sameer Sabir and focuses on creating innovative pain medicines. Its treatments, including the revolutionary Neural IceTM, relieve pain with a single, simple, safe, and drug-free injection that is locally targeted, non-addictive, and reasonably long-lasting.
“As we use the proceeds of this funding to enter into regulatory clinical studies, our goal is to deliver a simple injectable nerve block that lasts for several months, rather than a day or so.”
Sameer Sabir
